Sangamo Therapeutics (SGMOQ) FCF Margin (2010 - 2025)
Sangamo Therapeutics (SGMOQ) posted quarterly FCF Margin of 171.61% for Q4 2025, down 12241.0% year-over-year from N/an in Q4 2024, and up 96.51% quarter-over-quarter from 4916.01% in Q3 2025.
Sangamo Therapeutics (SGMOQ) FCF Margin (2010 - 2025) Analysis & Trends
Sangamo Therapeutics' FCF Margin history runs 16 years deep, the most recent figure standing at 171.61% for Q4 2025.
- In Q4 2025, FCF Margin fell 12241.0% year-over-year to 171.61%; the TTM figure through Dec 2025 stood at 246.03% (down 12731.0% YoY), while the FY2025 annual figure was 246.03%, down 12946.0% from the prior year.
- FCF Margin for Q4 2025 stood at 171.61%, up from 4916.01% in the prior quarter.
- The five-year high for FCF Margin was 23.01% in Q3 2024, with the low at 10212.68% in Q1 2024.
- The 5-year median for FCF Margin is 234.77% (2021), against an average of 1438.37%.
- The sharpest annual moves came in 2024 and 2025: FCF Margin sank 1016425 bps in 2024, then surged 980282 bps in 2025.
- Sangamo Therapeutics' FCF Margin stood at 198.57% in 2021, then declined by 19 bps to 236.96% in 2022, then slumped by 897 bps to 2361.8% in 2023, then jumped by 98 bps to 49.2% in 2024, then tumbled by 249 bps to 171.61% in 2025.
- Business Quant data shows SGMOQ's FCF Margin at 171.61% in Q4 2025, 4916.01% in Q3 2025, and 98.04% in Q2 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -171.61% |
| Sep 30, 2025 | -4,916.01% |
| Jun 30, 2025 | -98.04% |
| Mar 31, 2025 | -409.86% |
| Dec 31, 2024 | -49.20% |
| Sep 30, 2024 | 23.01% |
| Jun 30, 2024 | -7,422.47% |
| Mar 31, 2024 | -10,212.68% |
| Dec 31, 2023 | -2,361.80% |
| Sep 30, 2023 | -480.33% |
| Jun 30, 2023 | -810.83% |
| Mar 31, 2023 | -48.43% |
| Dec 31, 2022 | -236.96% |
| Sep 30, 2022 | -242.19% |
| Jun 30, 2022 | -183.67% |
| Mar 31, 2022 | -216.90% |
| Dec 31, 2021 | -198.57% |
| Sep 30, 2021 | -226.26% |
| Jun 30, 2021 | -232.59% |
| Mar 31, 2021 | -272.08% |